Prognostic Validation of the RANO-Resect Classification and Non-Contrast-Enhancing Tumor Resection: A Meta-Science Study in Glioblastoma Surgery.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 42153725.
- Also identified by DOI 10.1227/neu.0000000000004085.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Maximal safe resection correlates with improved overall survival (OS) and progression-free survival (PFS) in patients with glioblastoma (GBM). However, standardized classifications-particularly for resections extending beyond the contrast-enhancing (CE) tumor-remain inconsistent. The Response Assessment in Neuro-Oncology (RANO)-resect volumetric classification has demonstrated prognostic value in GBM, yet comparative validation across the literature remains limited. We aim to evaluate the prognostic performance of the RANO-resect classification for extent of resection (EOR) and compare its reproducibility in survival estimation relative to alternative, nonstandardized definitions of resection beyond the CE region. A search was conducted on May 23, 2024, identifying studies on GBM surgery that categorized EOR using the RANO-resect classification, as well as studies evaluating resection of non-CE tumor. Seventeen articles were included (n = 2606). Higher RANO-resect volumetric classes were associated with improved OS (P ≤ .0001) and PFS (P ≤ .0001): Class 1 (Supramaximal): OS 24.6 months, PFS 13.6 months; Class 2 (Maximal): OS 18 months, PFS 9.2 months; Class 3 (Submaximal): OS 13.5 months, PFS 8.2 months; and Class 4 (Biopsy): OS 8.2 months, PFS 4.8 months. Resection of non-CE tumor was associated with improved OS (MD = 6.4 months; 95% CI: 4.25-8.68; P ≤ .0001) and PFS (MD = 5.2 months; 95% CI: 3.4-6.6; P ≤ .0001) over complete CE tumor resection alone. Several different nonstandardized terminologies for non-CE tumor resection were identified. When applying the Class 1 RANO-resect definition, heterogeneity in OS outcomes was I2 = 0%, compared with 40% to 74% with alternative definitions. Maximal volumetric resection of non-CE tumor correlates with improved survival in patients with newly diagnosed GBM. We present the first direct comparison of the prognostic reproducibility between the RANO-resect framework for EOR compared with alternative nonstandardized definitions. Notably, the use of the RANO-resect volumetric classification was associated with more homogeneous survival estimates and greater OS predictability across studies, supporting its potential implementation in future clinical trials.